Safety and efficacy of MCO-010 optogenetic therapy in patients with Stargardt disease in USA (STARLIGHT): an open-label multi-center Ph2 trial.
Lam BL, Zak V, Gonzalez VH, Gregori NZ, Chavala SH, Batabyal S, Carlson M, Kim S, Ayyagari A, Chang J, Lane H, Choudry N, Koester J, Von Tress M, Piltz-Seymour J, Sharif NA, Tsang SH, Mahajan VB, Boyer DS, Ho AC, Barone SB, Mohanty SK.
Lam BL, et al.
EClinicalMedicine. 2025 Aug 14;87:103430. doi: 10.1016/j.eclinm.2025.103430. eCollection 2025 Sep.
EClinicalMedicine. 2025.
PMID: 40838197
Free PMC article.
The BCVA (mean SD) of the six treated eyes at baseline and 48-week follow-up was 22.8 9.87 (range 9-35), and 28.3 13.28 (range 4-42) ETDRS letters, respectively. The BCVA change from baseline was 7.2 11.74, 4.2 14.81, and 5.5 12.29 at 12, 24, and 48 weeks, resp …
The BCVA (mean SD) of the six treated eyes at baseline and 48-week follow-up was 22.8 9.87 (range 9-35), and 28.3 13.28 (range 4-42) E …